Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects
posted on 2020-04-08, 14:43authored byMartin Kankam, Rhonda Griffin, Jeffrey Price, Josée Michaud, Wei Liang, Mariona Bassas Llorens, Ana Sanz, Bradley Vince, David Vilardell
The above summary slide represents the opinions of
the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).